Ipca Laboratories has received a positive regulatory update from the United States Food and Drug Administration (US FDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Tarapur in Palghar district, Maharashtra.
The update follows a routine US FDA inspection conducted at the Tarapur API plant between December 1 and December 5, 2025. The company had earlier informed stock exchanges about the inspection under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
According to the Establishment Inspection Report (EIR) issued by the US FDA, the Tarapur manufacturing facility has been classified as “Voluntary Action Indicated (VAI)”. This classification means that while certain observations may have been noted during the inspection, the facility is considered to be in a minimally acceptable state of compliance with current Good Manufacturing Practices (cGMP).
A VAI status indicates that the US FDA does not intend to take any regulatory or enforcement action at this stage and that the facility can continue its operations and supply activities. Any observations raised are typically addressed through voluntary corrective actions by the company.